All news

Continued improvement in results and financial position / Full-year 2025 growth target confirmed

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, conducted numerous training sessions for surgeons around the world during the first half of 2025. In line with its strategy of international expansion and expertise sharing, the Group organized training courses in Europe, Latin America and Asia, supporting the launch of its product ranges in new markets and consolidating its network of spine surgery professionals.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received GMED (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral disc prostheses. This approval is a significant strategic milestone for the Group, ensuring the manufacturing and supply of its innovative ESP prostheses.

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Wednesday, June 4, 2025 at 2:00 p.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base.

• Annual revenue of €12 million (+14%) • Operating income close to breakeven • Reduction in net loss

Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que la Cour d’appel du Deleware (United States Court of Appeals for the third circuit) a décidé, dans un jugement rendu le 19 mars 2025, de confirmer la décision rendue en première instance et déboutant le groupe Spineway de sa demande d’exécution de la sentence arbitrale rendue à Genève qui faisait droit à la demande au fond de Spineway.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 2025 edition of the Arab Health trade fair, which was held at the Dubai World Trade Centre from January 27 to 30, 2025. This unmissable event for the medical sector in the Middle East offered Spineway the chance to strengthen its presence in the region and expand its distribution network.